Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

NCT02599480 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

296

Enrollment

OTHER

Sponsor class

Conditions

Hypertrophy, Left Ventricular

Interventions

DRUG: mirabegron
PROCEDURE: Echocardiography
PROCEDURE: Cardiac MRI
PROCEDURE: Maximal exercise capacity
PROCEDURE: Blood sampling
PROCEDURE: Endothelial function measurement
RADIATION: 18FDG-PET

Sponsor

Jean-Luc Balligand

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]